{"analyses":[{"ciLowerLimit":"0.552","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.105","estimateComment":"Log-rank test stratified by:\\* Region (Asia vs Non-Asia), \\* Number of organs with metastatic sites (0 to 2 vs \\>= 3), \\* Prior gastrectomy (Yes or No)","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0826","paramType":"Hazard Ratio (HR)","paramValue":"0.781","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.39","upperLimit":"8.28","value":"6.28"},{"groupId":"OG001","lowerLimit":"4.44","upperLimit":"6.34","value":"6.08"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan-Meier estimates was used.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an intravenous (IV) infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 milligrams per square meter (mg/m\\^2) on cycle 1 day 1 (C1D1) followed by subsequent doses of 600 mg/m\\^2 every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of capecitabine and oxaliplatin (CAPOX) treatment. Oxaliplatin was administered 130 mg/m\\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\\^2 twice daily (bid) on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21","id":"OG000","title":"CAPOX+ Zolbetuximab"},{"description":"Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C2D1 until participant met study treatment discontinuation criteria. Participants also received up to 8 treatments of CAPOX. Oxaliplatin was administered 130 mg/m\\^2 IV on day 1 of each cycle over 2 hours for a maximum of 8 treatments; Capecitabine was administered orally at 1000 mg/m\\^2 bid on days 1 through 14 of each cycle until the participant met study treatment discontinuation criteria. After a maximum of 8 treatments of oxaliplatin, participants may have continued to receive capecitabine taken twice daily on days 1 through 14 of each cycle at the investigator's discretion until the participant met study treatment discontinuation criteria. Each cycle was approximately 21 days.","id":"OG001","title":"CAPOX+ Placebo"}],"paramType":"MEDIAN","populationDescription":"FAS- All Objective Responders","reportingStatus":"POSTED","timeFrame":"From first response (CR/PR) until 61 months and 12 days","title":"Duration Of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}